TABLE 3.
OEA (n = 30) | Placebo (n = 30) | MD | 95% CI | p | |
---|---|---|---|---|---|
IL-6 (pg/mL) | |||||
Baseline | 18.67 (6.76) | 21.68 (8.78) | −3.01 | −7.11, 1.10 | 0.138c |
End | 16.98 (5.56) | 20.17 (6.56) | −5.19 | −11.97, 1.53 | 0.125d |
MD | −1.69 | −1.50 | |||
95% CI | - 4.49, 1.11 | −4.49, 1.48 | |||
p a | 0.236 | 0.324 | |||
IL-10 (ng/ml) | |||||
Baseline | 118.33 (74.37, 165.23) | 129.78 (90.51, 173.98) | −11.45 | −39.84, 16.93 | 0.429e |
End | 124.59 (89.44, 173.89) | 134.48 (84.39, 177.78) | −13.57 | −55.71, 29.89 | 0.529d |
MD | 6.26 | 4.70 | |||
p b | 0.193 | 0.234 | |||
IL-1β (pg/mL) | |||||
Baeline | 13.23 (4.49) | 15.11 (6.67) | −1.88 | −4.88, 1.11 | 0.205c |
End | 11.78 (3.39) | 14.82 (5.59) | −4.78 | −14.69, 6.09 | 0.101d |
MD | −1.45 | −0.29 | |||
95% CI | −3.76, 0.86 | −1.78, 1.18 | |||
p a | 0.218 | 0.701 | |||
TNF-α (ng/L) | |||||
Baseline | 53.71 (40.37, 157.23) | 50.12 (38.22, 111.56) | 3.59 | −23.93, 31.10 | 0.798e |
End | 51.97 (36.37, 145.23) | 49.36 (40.23, 127.87) | 4.55 | −12.81, 20.38 | 0.591d |
MD | −1.74 | −0.76 | |||
p b | 0.409 | 0.609 | |||
hs-CRP (mg/L) | |||||
Baseline | 7.14 (4.08, 17.33) | 5.78 (3.39, 12.98) | 1.36 | −1.00, 3.72 | 0.256e |
End | 4.56 (3.22, 21.11) | 3.33 (2.13, 19.67) | 2.49 | −3.11, 7.96 | 0.311d |
MD | −2.58 | −2.45 | |||
p b | 0.038 | 0.013 | |||
TAC (mmol/L) | |||||
Baseline | 0.81 (0.07) | 0.75 (0.17) | 0.06 | −0.008, 0.129 | 0.075c |
End | 1.33 (0.15) | 1.11 (0.19) | 0.22 | 0.02, 0.59 | 0.039 d |
MD | 0.52 | 0.36 | |||
95% CI | 0.16, 0.88 | 0.03, 0.70 | |||
p a | 0.005 | 0.032 | |||
GSH-Px (U/g Hb) | |||||
Baseline | 29.86 (6.89) | 31.07 (3.87) | −1.21 | −4.15, 1.72 | 0.411c |
End | 34.48 (9.16) | 33.59 (7.71) | 1.59 | −0.87, 3.94 | 0.173d |
MD | 4.62 | 1.89 | |||
95% CI | 1.68, 7.56 | −0.24, 4.01 | |||
p a | <0.001 | 0.081 | |||
Catalase (U/g Hb) | |||||
Baseline | 58.78 (11.77) | 61.55 (19.11) | −2.77 | −11.05, 5.50 | 0.511c |
End | 60.05 (19.22) | 61.12 (21.09) | −2.89 | −7.63, 3.83 | 0.412d |
MD | 1.27 | −0.43 | |||
95% CI | −1.62, 4.16 | −2.13, 1.26 | |||
p a | 0.387 | 0.621 | |||
SOD (U/mg Hb) | |||||
Baseline | 1693.12 (105.77) | 1733.11 (129.53) | −39.99 | −87.84, 7.87 | 0.095c |
End | 1933.13 (121.55) | 1823.97 (152.31) | 112.16 | 29.76, 207.09 | 0.018 d |
MD | 240.02 | 90.86 | |||
95% CI | 87.80, 392.3 | 20.83, 160.90 | |||
p a | <0.001 | 0.011 | |||
MDA (nmol/mL) | |||||
Baseline | 4.08 (0.55) | 3.88 (0.33) | 0.20 | −0.03, 0.43 | 0.088c |
End | 2.33 (0.97) | 3.33 (0.98) | −1.78 | −0.73, −2.87 | 0.003 d |
MD | −1.75 | −0.55 | |||
95% CI | −2.79, −0.71 | −1.22, 0.12 | |||
p a | 0.001 | 0.109 | |||
Ox-LDL (U/L) | |||||
Baseline | 76.21 (14.28) | 74.88 (21.87) | 1.33 | −8.29, 10.95 | 0.795c |
End | 71.55 (17.77) | 72.51 (24.61) | - 2.39 | −6.12, −1.77 | 0.001 d |
MD | −4.66 | −2.37 | |||
95% CI | −8.52, −0.81 | −6.28, 1.53 | |||
p a | 0.018 | 0.234 |
GSH-Px, glutathione peroxidase; hs-CRP, high-sensitivity C-reactive protein; IL, interleukin; MD, Mean/Median of difference; MDA, malondialdehyde; OEA, oleoylethanolamide; ox-LDL, oxidized-low density lipoprotein; SOD, superoxide dismutase; TAC; total antioxidant capacity; TNF-α, tumor necrosis factor-α. Mean (standard deviation) are presented for normally distributed data. Median (25th and 75th percentiles) are presented for data not normally distributed.
p-value based on Paired sample t-test.
b p-value based on Wilcoxon signed-rank test.
c p-value based on Independent sample t-test.
d p-value based on ANCOVA, adjusted for baseline values, age, changes in physical activity, energy intake, and BMI.
e p-value based on Mann-Whitney U test.
p < 0.05 is statistically significant.
Bold values indicates statistically significant differences (p < 0.05).